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Children may be the optimal target for HIV vaccine development as they generate
substantially more frequent and more potent broadly HIV neutralizing antibodies (bnAbs)
than adults. Development of a biomarker that correlates with neutralization breadth in this
group could function as a powerful tool to facilitate the development of an HIV vaccine.
Previously, we observed that this preferential ability in HIV-infected children over adults
to generate bnAbs is associated with an enrichment of circulating follicular helper T-cells
(TFH) with an effector phenotype, and the presence of IL-21 secreting HIV-specific TFH
within lymphoid tissue germinal centers (GC). In adults, bnAbs development has been
linked with high plasma levels of CXCL13, a chemoattractant for CXCR5-expressing TFH
cells to the lymph node GC. We sought to test this relationship in HIV-infected children,
but found no association between neutralization breadth and plasma levels of CXCL13, or
with the Th2 cytokines IL-4 and IL-13, or the TFH associated factor Activin A. However, we
did find an unexpected association between plasma IL-5 levels and bnAb development
in these children. Importantly, although CXCL13 correlated with total circulating TFH cells,
it was not associated with effector TFH. Additionally, raised CXCL13 expression was
associated with a lower CD4 percentage, higher viral load and a loss of immune function,
implying it is associated with progressive disease rather than HIV-specific GC activity in
these subjects. Taken together, our data suggests that IL-5 should be evaluated further as
a candidate plasma biomarker for HIV neutralization breadth and for monitoring vaccine
responses in the pediatric age group.
Keywords: CXCL13, IL-5, Activin A, broadly neutralizing antibodies (bnAbs), pediatric HIV, plasma markers, HIV
neutralization breadth, T-follicular helper cells (Tfh)
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INTRODUCTION
Recent HIV vaccine development strategies have highlighted the
unique potential contribution that can be made by the study
of the immune responses to HIV infection in children (1). In
response to the same gp120 vaccine, infants produced higher
magnitude anti-V1V2 antibodies than adults (2). Furthermore,
there is growing evidence that children are better at eliciting HIV-
specific antibody responses than adults and develop broad and
potent neutralizing antibodies as early as 2 years of life (3, 4).
Although the mechanistic details are not fully established, the
immune system in early life is specifically adapted, via the support
and regulation of TFH activity, to high frequency, high affinity
antibody production (5, 6).
Germinal centers (GC) of secondary lymphoid organs are the
primary site where a humoral immune response develops, but are
challenging to directly monitor in vaccine trials due to a lack of
routine access to lymphoid tissue. Recent attempts to use fine
needle aspirates show promise (7), but this invasive technique
is unlikely to be adopted for children. As an alternative various
studies of plasma markers of germinal center activity have been
conducted in adults to seek for correlates to GC activity (8–10).
T-follicular helper cells (TFH) are key regulators of the
antibody immunity, as they are critical for the formation of
GCs and for the development of high-affinity antibodies and
memory B cells. They restrict access to GCs for low-affinity B
cells, promote the survival of high-affinity B cells and trigger
B cell receptor (BCR) signaling. Crucially, signaling from TFH
cells drives the extensive somatic hypermutation necessary for
the generation of broadly neutralizing antibodies to HIV (11–
13). Although TFH cells mainly function in secondary lymphoid
tissue, they are also present in circulation and have been
associated with HIV neutralization breadth in adult (14) and
pediatric (6) infection. However, it remains unclear how the
frequency and phenotype of these cells in circulation reflects their
activity within the GC. Moreover, we have previously reported
the presence of high frequency IL-21 producing HIV-specific
GC TFH in lymphoid tissue of HIV-infected children that are
not readily detected in circulation (6). An alternative approach
is to study plasma markers that might correlate with TFH
activity within the GC. The CXCL13–CXCR5 chemokine axis, for
example, plays a central role in organizing both B-cell follicles
and GCs, as CXCR5 expressing TFH cells use CXCL13 to migrate
into the GCs of secondary lymphoid tissue (15). In adults,
it has been reported that plasma CXCL13 levels during early
HIV infection can predict the generation of broadly neutralizing
antibodies in chronic disease (8, 10). Additionally, elevated
plasma levels of CXCL13 have been observed in HIV-infected
individuals with high neutralization breadth (9). Additionally, a
positive correlation between circulating TFH and plasma CXCL13
levels has been observed in HIV-infected children (16). However,
whether CXCL13 correlates with GC activity or the development
of bnAbs against HIV in children is unknown. Using a previously
described cohort of HIV-infected children, in whom the frequent
development of bnAbs was associated with the TFH response (6),
we therefore tested the potential role of CXCL13 as a biomarker
of increased TFH activity and neutralization breadth. In addition,
we measured other candidate plasma markers of TFH activity:
Activin A has been identified as a powerful regulator of the
differentiation of TFH cells, which is antagonized by IL-2 (17);
and the Th2 cytokines IL-13, IL-4, and IL-5. The latter two have
been described as important stimulators of the GC reaction (18),
and impaired IL-5 production by T-cells has been previously
described as a prognostic marker of disease progression in HIV-
infected children (19).
MATERIALS AND METHODS
Study Participants
Plasma and peripheral blood mononuclear cells (PBMC) of
45 vertically HIV-1C clade-infected ART-naïve children with
matched neutralization data (4) and of pediatric uninfected
controls (n = 7) were studied. All children were recruited
from South African clinics at Kimberley Hospital (Kimberley,
South Africa) and Ithembalabantu Clinic (Durban, South Africa).
Uninfected controls were from the same ethnical background,
being mostly siblings of infected study participants. Notably, the
uninfected controls available for this study were significantly
older than the HIV-infected children studied (13-16.5 vs. 5.7-
10.8 years old). The clinical characteristics of the study cohort
are shown in Table 1. “High” neutralizers were defined by
neutralization of ≥81% of tested viruses (≥75% percentile; n =
13) and “low” neutralizers by neutralization of ≤44% of tested
viruses (≤25% percentile; n= 13). Viral load measurements were
performed as described previously (4). Informed consent was
obtained from all adult study participants or from the caregivers
of pediatric participants where appropriate. Additionally, assent
to participate in the study was given directly by children from the
age of 6 and above. Studies were approved by theUniversity of the
Free State Ethics Committee, Bloemfontein; Biomedical Research
Ethics Committee, University of KwaZulu-Natal, Durban; and
Research Ethics Committee, University of Oxford.
Sample Processing—PBMC and Plasma
Plasma was separated by centrifugation and crypopreserved
at −80◦C. PBMCs were isolated by Ficoll density gradient
centrifugation and stored in liquid nitrogen until use.
Virus Neutralization Assays
The ability of plasma from infected children to neutralize HIV
was measured against a panel of 16 tier 2 and tier 3 clade A,
B, and C viruses. Neutralization was determined by a reduction
in luciferase gene expression after a single round of infection of
JC53bl-13 cells, also known as TZM-bl cells (National Institutes
of Health AIDS Research and Reference Reagent Program), with
Env-pseudotyped viruses as previously described (4). Titer was
calculated as the reciprocal plasma/serum dilution causing a 50%
reduction of relative light units [median infective dose (ID50)].
Flow Cytometry and ICS Assays
PBMCs obtained at the same time point as plasma were
stained with fluorescent monoclonal antibodies against markers
associated with TFH cells as previously described (6). For a
subset of this cohort (n = 18), intracellular cytokine staining
assays for IL-4 (BD, FITC, 554484), IL-5 (BD, APC, 554397),
IL-13 (BD, V450, 561158), TNF-α (BD, AF700, 557996), and
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TABLE 1 | Clinical characteristics of study cohort.
Group n Age median (IQR) CD4/mm3 median (IQR) VL cp/ml median (IQR) Neutralization breadth (IQR)
Pediatric infected 45 7.6 (6.1–9.8) 790 (309–1067) 42,000 (14,000–132,834) 63 (44–81)
high neutralizers (high) 13 9.6 (6.6–10.8) 662 (315–1021) 62,000 (17,184–104,712) 88 (81–97)
low neutralizers (low) 13 7.0 (5.7–10.2) 1039 (806–1101) 37,207 (7080–194,243) 38 (22–44)
Pediatric uninfected 7 15.0 (13.0–16.5) N/A N/A N/A
N/A not applicable
INF-γ (BD, PE-Cy7, 557643) were performed. Briefly, cells were
stimulated with PMA/Ionomycin (at a final concentration of 4×
10−5M) in the presence of anti-CD28 and anti-CD49 (1 mg/ml),
Brefeldin A and Monensin (5 mg/ml) (BD biosciences) for 5 h,
followed by surface staining and intracellular staining. Rainbow
beads (BD biosciences) were run with every experiment and
compensation was adjusted to ensure longitudinal comparability
of experiments. Flow cytometry acquisition was performed on a
BD LSRFortessa within 5 h of staining and analyzed using FlowJo
version 9.9.5.
Plasma Assays
Plasma markers and neutralization breadth were determined
in matching time points in vertically infected children for
all available samples. Ex-vivo plasma levels of IL-5 were
quantified using a commercially available Luminex kit for human
cytokine/chemokine (Milliplex). Plasma samples were tested
in duplicate per the manufacturer’s recommendations. Plasma
levels of CXCL13 were quantified using a commercially available
enzyme-linked immunosorbent assay kit (R&D Systems) in
duplicate. Plasma levels of IL-4 and IL-13 were quantified using
high sensitivity ELISA kits from Invitrogen and Activin A and
IL-2 using ELISA kits from Sigma Aldrich.
Statistical Analysis
Statistical analyses were performed using Prism GraphPad
Software version 8.0.2 and the statistical software R (20). After
confirming a non-Gaussian distribution within the majority
of the parameters analyzed, the Wilcoxon-Mann–Whitney test
was used to compare continuous factors between two groups.
Correlation analyses were performed using the Spearman rank
correlation method with exact permutation p-values calculated.
All p-values are two-sided, and a p-value of< 0.05 was considered
significant. In scatterplots, median values are indicated. To
analyse the effect of the plasma markers measured (IL-
4, IL-13, IL-5, CXCL13, Activin A, IL-2) on neutralization
breath, we use a generalized linear model assuming a Poisson
distribution (21, 22).
RESULTS
Plasma CXCL13 Correlates With Disease
Progression but Not Neutralization Breadth
in HIV-Infected Children
To characterize potential plasma correlates of neutralization
breadth, we first measured plasma CXCL13, a proposed marker
of GC activity (9), in a cohort of antiretroviral (ART) naïve,
HIV-infected children (n = 45) with available neutralization
data from matching time points (4) (Table 1). In contrast
to previous reports in adults (9), plasma CXCL13 were not
correlated with HIV neutralization breadth when considering
all individuals; or when comparing individuals in the top
quartile of neutralizers (who neutralized ≥81% of tested viruses;
“high neutralizers”) to those in the bottom quartile (who
neutralized ≤44% neutralization breadth; “low neutralizers”;
Figure 1A and Table 1). However, we did observe a correlation
between the frequency of total blood TFH cells (defined
as CD3+CD4+CD45RA−CXCR5+CXCR3−PD1+ lymphocytes)
and CXCL13 plasma levels (r = 0.44, p = 0.004; Figure 1B)
within the whole pediatric cohort, including HIV-ve controls,
suggesting a potential association between these parameters.
Previously we observed that circulating effector TFH cells
(CCR7−) were associated with neutralization breadth, but central
TFH cells (CCR7
+) were not (6). Examining these groups
we find a correlation between CXCL13 and central TFH cells
(r = 0.43, p = 0.006), but not the functional effector TFH
subset (Figure 1C), consistent with lack of association between
CXCL13 and neutralization breadth. Moreover, when excluding
HIV uninfected children we find no significant associations
between CXCL13 and any TFH subset. We next examined
markers of disease progression and found that plasma CXCL13
was directly correlated with plasma viral load (r = 0.34;
p = 0.008; Figure 1D) and inversely correlated with CD4
percentage (r = −0.5; p = 0.0006; Figure 1E) and CD4
count (data not shown). Together these data suggest that, in
HIV-infected children, CXCL13 plasma levels do not correlate
with GC activity or TFH functionality, but rather with HIV
disease progression.
To further investigate this association, we assessed CD4
T-cell functionality in a subset of our cohort, for whom samples
were available, by stimulating PBMCs with PMA/Ionomycin
and measuring cytokine production in CD4 T-cells by
intracellular cytokine staining. We observe a strong inverse
correlation between the frequencies of cells producing the Th2
cytokines IL-4 and IL-13 and plasma CXCL13 (Figure 1F).
Similar trends were also detected for TNF-α and INF-γ
(Supplementary Figure S1), and maintained when only
considering HIV-infected children (data not shown). Overall
these data support the hypothesis that, in HIV-infected
children CXCL13 is not a good marker of GC activity, but
is rather associated with disease progression and loss of
immune function.
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FIGURE 1 | Plasma CXCL13 does not correlate with neutralization breadth in HIV-infected children. (A) Left: No correlation between plasma CXCL13 and
neutralization breadth at matching time points in a cohort of HIV-infected children (n = 45). Right: No differences in plasma CXCL13 levels between children with high
neutralization breadth (neutralization of ≥81% of viruses tested or ≥75% percentile; n = 13) and children with low neutralization breadth (neutralization of ≤44% of
viruses tested or ≤25% percentile; n = 13). (B) Positive correlation between plasma CXCL13 and frequencies of circulating T-follicular helper cells (TFH;
CD4+CD45RA−CXCR5+CXCR3−PD1+) in children including HIV-ve controls with available samples (infected: n = 33: uninfected: n = 7, green dots) (p = 0.004,
r = 0.44) (Table 1). (C) Circulating TFH cells were further subdivided into circulating central TFH cells (CCR7
+; left) and circulating effector TFH cells (CCR7
−; right).
Central TFH cells but not effector TFH cells were found to correlate significantly with CXCL13. (D) Positive correlation between CXCL13 and viral load and (E) an
inverse correlation with CD4 percentage was observed in HIV-infected children (n = 45). (F) Inverse correlations between IL-13 and IL-4 production by bulk CD4T
cells using intracellular cytokine staining assays in response to PMA/Ionomycin stimulation in a subgroup of children including HIV-ve controls (infected: n = 12;
uninfected n = 6, green dots) with available data. For comparison between 2 groups, Mann-Whitney tests were performed. Medians are indicated in scatter plots as a
solid black line. Calculation of correlations were made by Spearman’s rank correlation test.
Plasma IL-5 Correlates With Neutralization
Breadth in HIV-Infected Children
Having observed an association between plasma CXCL13 and
the frequency of IL-4/IL-13 secreting CD4 T-cells, we next
measured ex-vivo plasma levels of these cytokines and another
canonical Th2 cytokine, IL-5, and determined their association
with neutralization breadth. Surprisingly, of these cytokines only
IL-5, (Figure 2A) but not IL-4 and IL-13 (Figures 2B,C), was
elevated in children with high neutralization breadth (≥75%
percentile, neutralization of ≥81% of viruses tested, n = 13)
compared to those with low neutralization breadth (≤25%
percentile, neutralization of ≤44% of viruses tested, n = 13)
(p = 0.01). This corresponded with a positive correlation
between plasma IL-5 and neutralization breadth in HIV-infected
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FIGURE 2 | Plasma IL-5 correlates with neutralization breadth in HIV-infected
children. (A) Left: Children with high neutralization breadth (neutralization of
≥81% of viruses tested or ≥75% percentile; n = 13) have significantly
elevated levels of ex-vivo plasma IL-5 compared to children with low
neutralization breadth (neutralization of ≤44% of viruses tested or ≤25%
percentile; n = 13) (p = 0.01) (Table 1). Right: A positive correlation between
plasma IL-5 and neutralization breath within HIV-infected children (n = 45) (r =
0.3, p = 0.02). (B) As of (A) but showing ex vivo plasma IL-4 (n = 43) and (C)
IL-13 (n = 43) levels. Mann-Whitney test was performed. Medians are
indicated in scatter plots as a solid black line. For correlations, calculations
were made by Spearman’s rank correlation test.
children (r = 0.3, p = 0.02). To account for multiple statistical
comparisons, we conducted a multivariate Poisson regression
model analysis for all cytokines measured, and confirmed
a significant positive association between plasma IL-5 and
neutralization breadth (p = 0.0038). There was, however, no
correlation between plasma IL-5 and any of the circulating TFH
subsets or plasma CXCL13 (Supplementary Figure S2A) and
overall little IL-5 production of CD4 T-cells when stimulated
with PMA/ Ionomycin in a subset of the cohort with available
samples (Supplementary Figure S2B). In conclusion, plasma IL-
5, but not IL-4 or IL-13, correlates with neutralization breadth in
HIV-infected children.
No Association Between Plasma Activin a
and Neutralization Breadth in HIV-Infected
Children
Finally, we assessed a novel cytokine associated with TFH activity,
Activin A. This molecule has been demonstrated to be a potent
activator of TFH differentiation through a mechanism that is
antagonized by IL-2 (17).We thereforemeasured plasma levels of
both Activin A and IL-2 in our cohort of HIV-infected children.
To our knowledge, Activin A levels have not been assessed
in HIV-infected individuals and the impact of disease on this
cytokine was unknown. All individuals had high levels of Activin
A in their plasma, ranging between 2133 and 16,088 pg/ml.
Production of this cytokine may be altered by HIV infection
as plasma levels correlated weakly with CD4% and a similar
trend was observed for CD4 count (data not shown). However,
this did not reach significance and no correlation with VL was
observed (Figure 3A). Importantly, although there is a broad
range of Activin A expression, we observed no correlation with
neutralization breath in the cohort as a whole, and no significant
difference in Activin A levels between the top 25% (high) and the
bottom 25% (low) of subjects based on neutralization breadth
(Figure 3B). Because effect of Activin A on TFH is reported to
be antagonized by IL-2, we also tested the association between
the ratio of IL2:Activin A and neutralization breath and found
no correlation (Figure 3C). Moreover, plasma IL-2 alone does
not correlate with neutralization breadth (Figure 3D). Finally,
there was no correlation between either Activin A or IL-2 and
plasma levels of CXCL13 suggesting these cytokines are not
co-regulated (Figure 3E).
DISCUSSION
The immune responses of children offer some unique
perspectives that have the potential to inform HIV vaccine
efforts (1). A protective HIV vaccine will most likely require the
generation of bnAbs and this depends on an both an effective
GC response and TFH activity. Since direct monitoring of the
GC response in future pediatric vaccine trials is not feasible due
to lack of routine access to tissue, a plasma marker of the GC
response, TFH activity, and neutralization breadth would be of
great value. While in adults plasma CXCL13 levels during early
HIV infection can predict the generation of bnAbs in chronic
disease stage (8, 10) and individuals with high neutralization
breadth show elevated CXCL13 levels (9), this had not previously
been examined in pediatric patients.
Our observations that plasma CXCL13 correlated with disease
progression and general immune activation in pediatric patients
rather than with neutralization breadth is in line with previously
published findings where plasma CXCL13 was elevated in
adults with progressive HIV infection and correlated with the
inflammation-associated chemokine IP-10 (23). Furthermore,
plasma CXCL13 levels were elevated in HIV-infected children
compared to HIV-ve controls and correlated with viral load
in infected children (16, 24). In adults, bnAb development is
linked with viral loads and therefore with disease progression
(25), whereas in pediatrics bnAb development is also facilitated
by functional T-follicular helper and regulatory responses in the
setting of persistent high viremia (4, 6). Additionally, plasma
CXCL13 has been associated with immune activity in various
infectious and autoimmune diseases (23, 26–30), suggesting that
it may not be a specific marker of germinal center activity. This
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FIGURE 3 | No association between plasma Activin A and neutralization breadth in HIV-infected children. (A) Left: Correlation between CD4% and plasma Activin A
and Right: Lack of correlation between plasma Activin A and viral load in HIV-infected children (n = 39). (B) Left: No correlation between plasma Activin A and
neutralization breadth in the same cohort. Right: No differences in plasma Activin A levels between children with high neutralization breadth (neutralization of ≥81% of
viruses tested or ≥75% percentile; n = 13) and children with low neutralization breadth (neutralization of ≤44% of viruses tested or ≤25% percentile; n = 13). (C)
Lack of correlation between neutralization breadth and the ratio of plasma IL-2:Activin A (n = 39). (D) Left: No correlation between IL-2 levels and neutralization
breadth (n = 39). Right: No differences in plasma IL-2 levels between children with high (n = 13) and low neutralization breadth (n = 13). (E) Right: No correlation
between plasma Activin A and plasma CXCL13. Middle: No correlation between IL-2 and CXCL13 in plasma. Right: No correlation between plasma IL-2 and plasma
Activin A levels (n = 39). For comparison between 2 groups, Mann-Whitney tests were performed. Medians are indicated in scatter plots as a solid black line. For all
correlations, calculations were made by Spearman’s rank correlation test.
is supported by our observation that plasma CXCL13 correlated
with total circulating TFH but not the effector TFH subset
previously shown to be associated with neutralization breadth
in HIV-infected children (6). A potential caveat here is that our
correlations between circulating TFH and plasma CXCL13 levels
include HIV-ve controls, hence not limiting our observations
to the dynamics in HIV infection. Interestingly, in adult
viremic controlers, an inflammatory cytokine signature including
CXCL13 and IP-10 was associated with the development of
bnAbs (31). These data again demonstrate that interplay between
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virus, immune activation and neutralization breadth in pediatric
patients appears to be fundamentally distinct from adult infection
(4). It is important to note, however, that CXCL13 may still have
value as a marker of GC activity in the setting of childhood
vaccination, which was not tested here.
The finding that plasma IL-5, but not the other classic Th2
cytokines IL-13 and IL-4, correlated with neutralization breadth
within our cohort of HIV-infected children was unexpected.
Impaired IL-5 production of T-cells has been previously
described as a prognostic markers of disease progression in HIV-
infected children (19). In this present study, we did not observe
significant differences between the different clinical groups and
IL-5 production of CD4 T-cells was very limited in general.
It is therefore probable that other cell subsets are important
sources of plasma IL-5, including type 2 innate lymphoid cells,
mast cells, eosinophils and/or neutrophils (32, 33). Future work
will be required to identify the source of IL-5 and may shed
light on immune pathways that support antibody maturation.
However, recently published data support an association between
circulating CD8+CD57+ T-cells in viremic controllers and
neutralization breadth (34) and these cells were previously found
to secrete high levels of IL-5 (35). In addition, IL-5 is known to be
essential for antibody class switching in mice (36) and stimulates
B-cell proliferation (37), particularly of germinal center B-cells
(18). Finally, the fact that plasma levels of IL-5 correlated
with neutralization breadth in HIV-infected children may also
point to increased regulatory activity in these individuals. IL-
5 promotes the expansion and survival of antigen specific T
regulatory cells (Treg) (38), and treatment with recombinant
IL-5 leads to an expansion of Treg and reduces pathology in
experimental autoimmunity (39). Indeed, the fact that we observe
no correlation between plasma IL-5 and circulating effector TFH,
might suggest that the role for IL-5 does not relate to the germinal
center activity. However, further work in an extended cohort
of individuals or in the animal model is required to test these
hypotheses. It would also be interesting to evaluate additional
predictive plasma markers of neutralization breadth as has been
done for adult infection (8, 10).
A biomarker which predicts GC activity, TFH activity, and
neutralization breadth in the pediatric population would offer
a powerful tool for vaccine development. Our results suggest
that IL-5 is a potential candidate. In addition, exploration
of the biology behind this association may improve our
understanding of how broadly neutralizing antibodies develop in
this key population.
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